Mankind Pharma

Mankind Pharma FCF/Debt

The Free Cash Flow to Debt Ratio of Mankind Pharma (MANKIND.NS) as of Nov 17, 2026 is 29.94 %. In the previous year, Free Cash Flow to Debt Ratio was 22.94 % — a change of 30.51% (higher).

FCF/Debt

29.94 %

YoY

30.51%

Last updated:

Free Cash Flow to Debt Ratio of Mankind Pharma is 2026 29.94 % . Free Cash Flow to Debt Ratio of Mankind Pharma was 2025 22.94 % . It decreases by 30.51% higher compared to the previous year.

The Mankind Pharma FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2019
112.01 INR
Jan 1, 2020
655.40 INR
Jan 1, 2021
342.78 INR
Jan 1, 2022
-163.30 INR
Jan 1, 2023
575.94 INR
Jan 1, 2024
854.41 INR
Jan 1, 2025
22.94 INR
Jan 1, 2026
29.94 INR
The Mankind Pharma FCF/Debt history
YEARFCF/DebtYoY
29.94 %+30.51%
22.94 %-97.32%
854.41 %+48.35%
575.94 %-452.68%
-163.30 %-147.64%
342.78 %-47.70%
655.40 %+485.12%
112.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mankind Pharma Stock analysis

What does Mankind Pharma do? Mankind Pharma Ltd develops, manufactures, and markets pharmaceutical formulations across therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, and respiratory treatments. The company's portfolio includes brands such as Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, and Monticop, targeting acute and chronic conditions. These products are sold to healthcare providers, hospitals, and pharmacies across India, serving patients in diverse medical needs. The firm generates revenue through the sale of prescription and over-the-counter pharmaceuticals, leveraging its extensive portfolio in multiple therapeutic segments. Mankind Pharma focuses on therapeutic areas like anti-diabetic, dermatology, gynecology, pain/analgesics, urology, ophthalmology, and antiviral treatments, with brands such as Glimestar for diabetes and Manforce (Rx) for sexual health. The company's consumer healthcare products complement its prescription offerings, expanding market reach. Revenue streams come from the direct sale of branded formulations to distributors and retail chains, with no mention of external partnerships or additional services beyond pharmaceutical manufacturing and marketing. The company's therapeutic portfolio spans anti-malarial, blood-related, hormones, antineoplastic, hepatoprotective, and parenteral treatments, supported by brands like Cefakind for infections and Zenflox for respiratory issues. Sales are driven by its diverse product range covering both prescription and consumer healthcare segments, with no indication of licensing agreements or third-party collaborations. Mankind Pharma's revenue model relies solely on the marketing and distribution of its own branded pharmaceutical products within India's healthcare ecosystem. Mankind Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mankind Pharma stock

Free Cash Flow to Debt Ratio of Mankind Pharma is 29.94 % in 2026.

Free Cash Flow to Debt Ratio of Mankind Pharma changed from 22.94 % to 29.94 %, representing a 30.51% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Mankind Pharma since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Mankind Pharma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Mankind Pharma

All Key Metrics — Mankind Pharma